Biotech entity

Scantox

Company

acquisition is the sole category represented across all 1 tracked stories. Of the tracked stories, 1 of 1 also mention DuplexSeq, the most common co-covered peer. The tracked stories average 2 original sources each. Scantox appears in 1 tracked Biotech story from February 26, 2026.

Last mentioned: Feb 26, 2026

Entity pulse

Recent coverage · Scantox

1 story
5 avg impact
0% positive
0% negative
  • 100% neutral

Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.

What the coverage shows about Scantox

acquisition is the sole category represented across all 1 tracked stories. Of the tracked stories, 1 of 1 also mention DuplexSeq, the most common co-covered peer. The tracked stories average 2 original sources each. Scantox appears in 1 tracked Biotech story from February 26, 2026.

Stories tracked
1
Sources per story
2

Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 18 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.

Coverage cohort

Appears alongside

Other entities that clear the same relevance threshold in stories also covering Scantox. Shared-story counts are live from our verified record — not editorial picks.

Timeline

  1. Integration Phase

    Transfer of DuplexSeq equipment and IP to Scantox facilities and staff training.

  2. Acquisition Announced

    Scantox officially announces the purchase of TwinStrand's nonclinical genomics safety business.

  3. Full Commercial Launch

    Scantox expected to offer full-scale DuplexSeq services as part of its standard safety assessment packages.

Stories mentioning Scantox 1

Acquisitions Neutral

Scantox Bolsters Genetic Tox Portfolio with TwinStrand’s DuplexSeq Acquisition

Scantox has acquired the DuplexSeq™ nonclinical genomics safety business from TwinStrand Biosciences, integrating ultra-sensitive sequencing technology into its pre-clinical service suite. This strategic move positions Scantox as a leader in high-resolution genetic toxicology, offering pharmaceutical clients unprecedented accuracy in identifying mutagenic risks.

2 sources

Scantox is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.

See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.